Novartis AG (NVS)

NYSE: NVS · Real-Time Price · USD
128.05
-0.66 (-0.51%)
At close: Sep 9, 2025, 4:00 PM
129.59
+1.54 (1.20%)
After-hours: Sep 9, 2025, 7:54 PM EDT
-0.51%
Market Cap248.23B
Revenue (ttm)55.19B
Net Income (ttm)13.65B
Shares Out 1.94B
EPS (ttm)6.85
PE Ratio18.18
Forward PE15.02
Dividend$2.60 (2.03%)
Ex-Dividend DateMar 12, 2025
Volume1,009,094
Open128.32
Previous Close128.71
Day's Range127.90 - 128.58
52-Week Range96.06 - 130.46
Beta0.55
AnalystsHold
Price Target123.67 (-3.42%)
Earnings DateOct 28, 2025

About NVS

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]

Sector Healthcare
IPO Date Nov 18, 1991
Employees 75,883
Stock Exchange NYSE
Ticker Symbol NVS
Full Company Profile

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $123.67, which is a decrease of -3.42% from the latest price.

Price Target
$123.67
(-3.42% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion. To...

Other symbols: TRML
17 hours ago - Invezz

This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.

Novartis agrees to acquire Tourmaline Bio in an all-cash deal worth around $1.4 billion.

Other symbols: TRML
18 hours ago - Barrons

Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range

Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what's been a flurry of acquisitions at a similar price point.

Other symbols: TRML
20 hours ago - Market Watch

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

The deal will boost the Swiss pharmaceutical company's cardiovascular drug pipeline.

Other symbols: TRML
1 day ago - WSJ

Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion

Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday.

Other symbols: TRML
1 day ago - Reuters

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a long-acti...

Other symbols: TRML
1 day ago - GlobeNewsWire

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targe...

Other symbols: TRML
1 day ago - GlobeNewsWire

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

6 days ago - Reuters

Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs

Swiss drugmaker Novartis has signed a licensing and options deal with Argo Biopharmaceutical for up to $5.2 billion to gain access to its experimental cardiovascular drugs, the privately held biotech ...

6 days ago - Reuters

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline License to an additional Argo siRNA candidate c...

6 days ago - PRNewsWire

Novartis: Pipeline Progress And Buyback Drive Upside

Novartis delivered strong Q2 results with 24% net income growth and robust sales from key drugs like Kisqali and Pluvicto, supporting our positive outlook. Despite generic competition and tariff conce...

6 days ago - Seeking Alpha

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Arrowhead Pharmaceuticals said on Tuesday it will receive up to $2 billion from Novartis for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as Pa...

Other symbols: ARWR
7 days ago - Reuters

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually opt...

10 days ago - GlobeNewsWire

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

STOCKHOLM , Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis ...

15 days ago - PRNewsWire

New Novartis ESC data highlights strength of cardiovascular portfolio

PRESS RELEASE Two VictORION studies will highlight Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy Lp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen...

23 days ago - GlobeNewsWire

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated ...

4 weeks ago - GlobeNewsWire

Swiss government to meet pharma firms to discuss US tariffs

The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on it...

4 weeks ago - Reuters

Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease

The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.

4 weeks ago - WSJ

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's dis...

4 weeks ago - PRNewsWire

Novartis weighs deal for biotech Avidity Biosciences, FT reports

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter

Other symbols: RNA
4 weeks ago - Reuters

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

5 weeks ago - WSJ

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

5 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

5 weeks ago - CNBC Television

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic car...

5 weeks ago - PRNewsWire

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

5 weeks ago - Forbes